Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Anti-ischemic Effects of Nimesulide, a Cyclooxygenase-2 Inhibitor on the Ischemic Model of Rabbit Induced by Isoproterenol

  • Saeed, Sheikh Arshad (Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical Sciences, University of Karachi) ;
  • Ahmed, Sagheer (Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical Sciences, University of Karachi)
  • Published : 2006.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

The objective was to devise an animal model of myocardial infarction (MI) against which cardioprotective drugs might be tested. We describe the effects of nimesulide, a COX experience with development and validation of such a model. The rabbit was chosen in preference to rodents because its heart and cardiac circulation more closely resemble those of human. Thus, the cardiovascular system of anaesthetized male rabbits, 1 to 1.5 kg (n=11), was stressed by a single bolus intravenous injection of isoprenaline (ISP), 65 mg/kg. The effects of the injection were followed for sixteen days and were evaluated in four ways: 1) measurements of creatinine kinase isozyme and troponin-I (TPI) in serum 2) Electrocardiographic (ECG) changes (ST elevation and Q wave development) 3) Cardiac histopathology observed in tissue sections of the isolated of the heart. The histopathological analysis showed that rabbit heart on 2nd day after ISP injection showed changes of coagulation necrosis. Day 4 total coagulation with the loss of nuclear and striation associated with heavy interstitial infiltrate of neutrophils was found. Day 8 after infarction showed collagen deposition with capillary channels in between the remaining islands of myocytes in the infarcted area. On the 16th day scarring was complete. Coronary perfusion rates (CPR) and heart rate (HR) of the infarcted and nimesulide (a COX-2 inhibitor) treated rabbits displayed significant improvement (n=11) on each corresponding day after infarction as compared to the infarcted and saline treated rabbits (P<0.05). All four indices revealed similarities with effects commonly associated with MI in humans.

Keywords

References

  1. Adams, J. E. 3rd., Bodor, G. S., Davila-Roman, V.G., Delmez, J. A., Apple, F. S., Ladenson, J. H., and Jaffe, A. S., Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation, 88, 101-106 (1993) https://doi.org/10.1161/01.CIR.88.1.101
  2. Baker, C. S., Hall, R. J., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., and Polak, J.M., Cyclooxygenase- 2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol., 19, 646-655 (1999) https://doi.org/10.1161/01.ATV.19.3.646
  3. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D. J., Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation, 102, 840- 845 (2000) https://doi.org/10.1161/01.CIR.102.8.840
  4. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos- Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N. Engl. J. Med., 243, 1520-1528 (2000)
  5. Bonow, R. O., Lipson, L. C., Shaheen, F. H., Capurro, N. L., Inser, J. M., Roberst, W.C., Goldstein, R. E., and Epstein, S.E., Lack of effect of aspirin on myocardial infarct size in dogs. Am. J. Cardiol., 47, 258-264 (1981) https://doi.org/10.1016/0002-9149(81)90395-7
  6. Cai, H. and Harrison, D. G., Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Cirs. Res., 87, 840-844 (2000) https://doi.org/10.1161/01.RES.87.10.840
  7. Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., Michel, B., Luscher, T. F., Noll, G., and Ruschitzka, F., Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 107, 405-409 (2003) https://doi.org/10.1161/01.CIR.0000051361.69808.3A
  8. Duffy, S. J., Castle, S. F., Harper, R. W. et al., Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilatation, and flow-mediated dilation in human coronary circulation. Circulation, 100, 1951-1957 (1999) https://doi.org/10.1161/01.CIR.100.19.1951
  9. Heitzer, T., Just, H., and Munzel, T., Antioxidant vitamin C improves and endothelial dysfunction in chronic smokers. Circulation, 94, 6-9 (1996) https://doi.org/10.1161/01.CIR.94.1.6
  10. Koenig, W., Inflammation and coronary heart disease: an overview. Caridol. Rev., 9, 31-35 (2001) https://doi.org/10.1097/00045415-200101000-00007
  11. Langendorff. Pfluners Arch. Ges. Physiol., 190, 280 (1985)
  12. Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., and Smith, W. L., Acetylation of human prostaglandin endoperoxide synthase- 2 (cyclooxygenase-2) by aspirin. J. Biol. Chem., 269, 13207- 13215 (1994)
  13. Mobert, J. and Becker, B. F., Cyclooxygenase inhibition aggravates ischaemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J. Am. Coll. Cardiol., 31, 1687-1694 (1998) https://doi.org/10.1016/S0735-1097(98)00158-2
  14. Mukerjee, D., Nissen, S. E., and Topol, E. J., Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286, 954-959 (2001) https://doi.org/10.1001/jama.286.8.954
  15. Mukerjee, D., Selective Cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol., 63, 817-21 (2002) https://doi.org/10.1016/S0006-2952(02)00842-0
  16. O'Banion M., Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Critc. Rev. Neurobiol., 13, 45-82 (1999) https://doi.org/10.1615/CritRevNeurobiol.v13.i1.30
  17. Rosalki, S. B., An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med., 69, 696- 705 (1967)
  18. Saeed, S. A., Atiq, M., Virani, S., and Gilani, A. H., New vistas in the therapeutic uses of aspirin. Res. Commun. Pharmacol. Toxicol., 6, 277-296 (2001)
  19. Saeed, S. A., Gilani, A. H., Sultan, B. H., Karim, R. M., and Shah, B. H., Myocardial ischemia and infarction in isoprenalinetreated rabbits: Role of cyclooxygenases. Bichem. Soc. Trans., 26, S342 (1998) https://doi.org/10.1042/bst026s342
  20. Saito, T., Rodger, I. W., Hu, F., Shennib, H., and Giaid, A., Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biphys. Res. Commun., 273, 772-775 (2000) https://doi.org/10.1006/bbrc.2000.3010
  21. Schonbeck, U., Sukhova, G. K., Graber, P., Coulter, S., and Libby, P., Augmented expressoin of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol., 155, 1281- 1291 (1999) https://doi.org/10.1016/S0002-9440(10)65230-3
  22. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S., Gastrointestinal toxicity with celecoxib vs nonsterodial anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study. A randomized control trial. JAMA, 284, 1247- 1255 (2000) https://doi.org/10.1001/jama.284.10.1247